ImmunoPrecise Antibodies Ltd. Files Form 6-K
Ticker: HYFT · Form: 6-K · Filed: Mar 20, 2024 · CIK: 1715925
Sentiment: neutral
Topics: filing, regulatory-update
TL;DR
IPA files 6-K on 3/20, includes press release. Check for updates.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on March 20, 2024, reporting information as of that date. The filing includes a press release dated March 20, 2024, as Exhibit 99.1. The company's principal executive offices are located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Why It Matters
This filing provides updated information and potentially significant news from ImmunoPrecise Antibodies Ltd. to investors and the market.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to disseminate information, rather than indicating a significant event or financial distress.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- March 20, 2024 (date) — Filing date and press release date
- Kristin Taylor (person) — Chief Financial Officer
- 001-39530 (other) — SEC File Number
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically used to report material information that the company has made or is required to make public in its home country.
What is included as an exhibit with this filing?
Exhibit 99.1 is a Press Release dated March 20, 2024.
Who signed this report on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor, Chief Financial Officer, signed the report.
What is the fiscal year end for ImmunoPrecise Antibodies Ltd.?
The fiscal year end for ImmunoPrecise Antibodies Ltd. is April 30.
Where are the principal executive offices of ImmunoPrecise Antibodies Ltd. located?
The principal executive offices are located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Filing Stats: 157 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-03-20 12:02:27
Filing Documents
- form6k.htm (6-K) — 4KB
- exhibit99-1.htm (EX-99.1) — 9KB
- exhibit99-1x001.jpg (GRAPHIC) — 4KB
- 0001062993-24-006862.txt ( ) — 21KB
From the Filing
ImmunoPrecise Antibodies Ltd.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 . Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: March 20, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer EXHIBIT INDEX 99.1 Press Release dated March 20, 2024